Companies Vera Therapeutics, Inc.
Vera Therapeutics (VERA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Vera Therapeutics, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers28th pct.Of 18 peer CEOs
CEO pay, last three years
- $3,429,733FY2023
- $5,648,201FY2024
- $6,986,410FY2025
CEO total pay was $6,986,410 in fiscal 2025, up from $5,648,201 in fiscal 2024.
FY2025: salary $660,000 · bonus $0 · stock awards $2,356,285 · option awards $3,415,725
Executives and directors
David Johnson · COORobert Brenner · Chief Medical OfficerMarshall Fordyce · CEOSean Grant · CFOWilliam Turner · Chief Regulatory OfficerAndrew Cheng, M.D., Ph.D · Independent DirectorBeth Seidenberg, M.D · Independent DirectorChristopher Hite · Independent DirectorChristy Oliger · Independent DirectorJames R. Meyers · Independent DirectorKimball Hall · Independent DirectorMaha Katabi, Ph.D · Independent DirectorMichael M. Morrissey, Ph.D · Chair of the BoardPatrick G. Enright · Independent DirectorScott Morrison · Independent Director
Frequently asked questions
Who was the highest-paid executive at Vera Therapeutics, Inc. in fiscal 2025?
As disclosed, Marshall Fordyce (President and Chief Executive Officer) was the highest-paid executive at Vera Therapeutics, Inc. in fiscal 2025, with total compensation of $6,986,410.
How does Vera Therapeutics, Inc.'s chief executive pay compare to its disclosed peer group?
As disclosed, Marshall Fordyce's total compensation ranked at the 28th percentile of Vera Therapeutics, Inc.'s disclosed peer group.
What is Vera Therapeutics, Inc.'s CEO-to-median employee pay ratio?
As disclosed, Vera Therapeutics, Inc.'s CEO-to-median employee pay ratio was 16.3:1.
How did shareholders vote on Vera Therapeutics, Inc.'s executive compensation?
As disclosed, 95.88% of shareholders supported Vera Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Vera Therapeutics, Inc. spend in total on board compensation for fiscal 2025?
As disclosed, Vera Therapeutics, Inc. reported total board compensation of $449,891 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Marshall Fordyce | $660,000 | $0 | $2,356,285 | $3,415,725 | $554,400 | $0 | $0 | $6,986,410 |
| President and Chief Executive Officer | ||||||||
| David Johnson | 510,000 | 0 | 784,942 | 1,137,870 | 285,600 | 0 | 3,000 | 2,721,412 |
| Chief Operating Officer | ||||||||
| Robert Brenner | 509,000 | 0 | 784,942 | 1,137,870 | 285,040 | 0 | 3,000 | 2,719,852 |
| Chief Medical Officer | ||||||||
| Sean Grant | 507,000 | 0 | 784,942 | 1,137,870 | 283,920 | 0 | 3,000 | 2,716,732 |
| Chief Financial Officer | ||||||||
| William Turner | 473,000 | 0 | 656,550 | 951,750 | 264,880 | 0 | 0 | 2,346,180 |
| Chief Regulatory Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Marshall Fordyce | $6,986,410 | $5,648,201 | $3,429,733 | ↑ +1,338,209 |
| David Johnson | 2,721,412 | — | — | — |
| Robert Brenner | 2,719,852 | 4,445,802 | — | ↓ −1,725,950 |
| Sean Grant | 2,716,732 | 2,246,532 | 1,761,820 | ↑ +470,200 |
| William Turner | 2,346,180 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
| CEO STI target (% of salary) | 60% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | — |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Johnson | RSU | 2025-02-18 | — | — | 26,900 | — | $784,942 |
| Robert Brenner | RSU | 2025-02-18 | — | — | 26,900 | — | 784,942 |
| Marshall Fordyce | RSU | 2025-02-18 | — | — | 80,750 | — | 2,356,285 |
| William Turner | RSU | 2025-02-18 | — | — | 22,500 | — | 656,550 |
| David Johnson | OPTION | 2025-02-18 | — | — | 53,800 | — | 1,137,870 |
| Marshall Fordyce | OPTION | 2025-02-18 | — | — | 161,500 | — | 3,415,725 |
| Robert Brenner | OPTION | 2025-02-18 | — | — | 53,800 | — | 1,137,870 |
| William Turner | OPTION | 2025-02-18 | — | — | 45,000 | — | 951,750 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Johnson | $784,942 | $0 | $1,137,870 | 0.0% |
| Robert Brenner | 784,942 | 0 | 1,137,870 | 0.0% |
| Marshall Fordyce | 2,356,285 | 0 | 3,415,725 | 0.0% |
| William Turner | 656,550 | 0 | 951,750 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Sean Grant | Option | 3,750 | 20.94 | — |
| Marshall Fordyce | Option | 7,340 | 20.94 | — |
| Sean Grant | RSU | 19,687 | — | 996,950 |
| William Turner | RSU | 22,500 | — | 1,139,400 |
| Sean Grant | RSU | 26,900 | — | 1,362,216 |
| David Johnson | RSU | 26,900 | — | 1,362,216 |
| Robert Brenner | RSU | 26,900 | — | 1,362,216 |
| William Turner | Option | 35,625 | 29.18 | — |
| Sean Grant | Option | 42,592 | 29.18 | — |
| David Johnson | Option | 42,592 | 29.18 | — |
| Robert Brenner | Option | 42,592 | 29.18 | — |
| Sean Grant | Option | 50,782 | 16.8 | — |
| Sean Grant | Option | 58,334 | 7.87 | — |
| Marshall Fordyce | RSU | 59,062 | — | 2,990,900 |
| Marshall Fordyce | RSU | 80,750 | — | 4,089,180 |
| David Johnson | Option | 103,334 | 36.29 | — |
| Marshall Fordyce | Option | 127,855 | 29.18 | — |
| Marshall Fordyce | Option | 131,250 | 7.87 | — |
| William Turner | Option | 143,230 | 15.53 | — |
| Marshall Fordyce | Option | 152,344 | 16.8 | — |
| Robert Brenner | Option | 182,292 | 15.36 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| James R. MeyersIndependent · Audit · Newly elected | $4,891 | — | $735,750 | — | $0 | $740,641 |
| Michael M. Morrissey, Ph.DIndependent · Board Chair · Audit · Nominating and Corporate Governance | 90,000 | — | 296,660 | — | 0 | 386,660 |
| Scott MorrisonIndependent · Audit (Chair) | 60,000 | — | 296,660 | — | 0 | 356,660 |
| Patrick G. EnrightIndependent · Compensation (Chair) | 55,000 | — | 296,660 | — | 0 | 351,660 |
| Beth Seidenberg, M.DIndependent · Audit | 50,000 | — | 296,660 | — | 0 | 346,660 |
| Maha Katabi, Ph.DIndependent · Nominating and Corporate Governance | 50,000 | — | 296,660 | — | 0 | 346,660 |
| Andrew Cheng, M.D., Ph.DIndependent · Compensation · Nominating and Corporate Governance | 47,500 | — | 296,660 | — | 0 | 344,160 |
| Kimball HallIndependent · Compensation | 47,500 | — | 296,660 | — | 0 | 344,160 |
| Christy OligerIndependent · Nominating and Corporate Governance | 45,000 | — | 296,660 | — | 0 | 341,660 |
| Marshall Fordyce, M.DEmployee director | — | — | — | — | — | 0 |
| Christopher HiteIndependent | — | — | — | — | 0 | — |
Board fee structure and ownership guideline
| Annual cash retainer | $40,000 |
|---|---|
| Annual equity retainer | $400,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 / 7,500 / 5,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $449,891 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $449,891 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Vera Therapeutics as a peer
Companies that benchmark against VERA
10 companies name VERA as a compensation peer
The list of companies that name VERA as a peer is temporarily unavailable — recheck shortly.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
IMVT Immunovant Inc.RNAM Avidity Biosciences Inc.AKRO Akero Therapeutics Inc.CRNX Crinetics Pharmaceuticals Inc.PTGX Protagonist Therapeutics Inc.ANAB AnaptysBio Inc.IDYA IDEAYA Biosciences Inc.SLNO Soleno Therapeutics Inc.ACLX Arcellx Inc.SYRE Spyre Therapeutics Inc.KYMR Kymera Therapeutics Inc.GPCR Structure Therapeutics Inc.NMRA Neumora Therapeutics Inc.SMMT Summit Therapeutics Inc.COGT Cogent Biosciences Inc.PLRX Pliant Therapeutics Inc.SNDX Syndax Pharmaceuticals Inc.CLDX Celldex Therapeutics Inc.
Peer reciprocity
The companies Vera Therapeutics, Inc. names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Summit Therapeutics Inc. | 2025 | Mahkam Zanganeh | $616,500 | $0 | $245,021,384 | $0 | $246,047,279 |
| 2 | Soleno Therapeutics Inc. | 2024 | Anish Bhatnagar | 640,000 | 46,883,000 | 3,231,230 | 403,200 | 51,160,430 |
| 3 | Cogent Biosciences Inc. | 2025 | Andrew Robbins | 724,554 | 12,993,250 | 13,447,680 | 561,600 | 27,762,684 |
| 4 | Arcellx Inc. | 2024 | Rami Elghandour | 653,288 | 9,342,069 | 10,850,151 | 0 | 21,402,668 |
| 5 | Immunovant Inc. | 2026 | Eric Venker | 636,618 | 0 | 19,010,639 | 0 | 20,158,767 |
| 6 | Avidity Biosciences Inc. | 2024 | Sarah Boyce | 659,900 | 10,748,480 | 2,157,090 | 594,000 | 14,176,480 |
| 7 | Protagonist Therapeutics Inc. | 2025 | Dinesh Patel | 715,500 | 5,839,204 | 5,618,010 | 686,880 | 12,871,506 |
| 8 | Crinetics Pharmaceuticals Inc. | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 9 | Akero Therapeutics Inc. | 2024 | Andrew Cheng | 686,000 | 2,879,155 | 6,489,100 | 411,600 | 10,465,855 |
| 10 | Ideaya Biosciences Inc. | 2025 | Yujiro Hata | 700,000 | 0 | 8,418,840 | 378,000 | 9,512,640 |
| 11 | Kymera Therapeutics Inc. | 2025 | Nello Mainolfi | 693,000 | 0 | 7,318,859 | 519,750 | 8,545,609 |
| 12 | Structure Therapeutics Inc. | 2025 | Raymond Stevens | 672,094 | 2,387,996 | 4,846,926 | 508,871 | 8,429,887 |
| 13 | Syndax Pharmaceuticals Inc. | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 14 | Vera Therapeutics, Inc. | 2025 | Marshall Fordyce | 660,000 | 2,356,285 | 3,415,725 | 554,400 | 6,986,410 |
| 15 | Spyre Therapeutics Inc. | 2025 | Cameron Turtle | 665,000 | 0 | 5,552,886 | 475,475 | 6,707,361 |
| 16 | AnaptysBio Inc. | 2025 | Daniel Faga | 706,011 | 1,592,001 | 3,345,653 | 465,968 | 6,133,943 |
| 17 | Pliant Therapeutics Inc. | 2025 | Bernard Coulie | 682,000 | 1,810,250 | 2,713,750 | 204,600 | 5,462,901 |
| 18 | Celldex Therapeutics Inc. | 2025 | Anthony Marucci | 785,804 | 0 | 4,027,590 | 0 | 5,366,709 |
| 19 | Neumora Therapeutics Inc. | 2025 | Paul Berns | 700,000 | 0 | 3,326,181 | 504,000 | 4,562,461 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Vera Therapeutics, Inc. | not disclosed | RSU 50 · Options 50 | not disclosed | Alpine Rewards |
| Akero Therapeutics Inc. | 100% | not disclosed | not disclosed | Pearl Meyer & Partners, LLC |
| AnaptysBio Inc. | 110% | not disclosed | No | Alpine Rewards |
| Arcellx Inc. | 140% | not disclosed | No | Meridian Compensation Partners |
| Avidity Biosciences Inc. | not disclosed | Option 80 · RSU 20 | not disclosed | Alpine Rewards, LLC |
| Celldex Therapeutics Inc. | 100% | Options 100 | not disclosed | Aon (Human Capital Solutions practice, a division of Aon plc) |
| Cogent Biosciences Inc. | 135% | not disclosed | No | Compensia |
| Crinetics Pharmaceuticals Inc. | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Ideaya Biosciences Inc. | 90% | Options 100 | not disclosed | Aon (Aon plc, Talent Solutions practice) |
| Immunovant Inc. | 110% | not disclosed | No | Compensia |
| Kymera Therapeutics Inc. | 125% | not disclosed | No | Alpine Rewards |
| Neumora Therapeutics Inc. | not disclosed | Options 100 | not disclosed | Alpine Rewards, LLC |
| Pliant Therapeutics Inc. | not disclosed | Option 66.67 · RSU 33.33 | not disclosed | Pearl Meyer; Alpine Rewards |
| Protagonist Therapeutics Inc. | 160% | Options 50 · RSU 50 | not disclosed | Aon Human Capital Solutions |
| Soleno Therapeutics Inc. | not disclosed | not disclosed | not disclosed | Aon plc |
| Spyre Therapeutics Inc. | 130% | Option 100 | not disclosed | Alpine Rewards |
| Structure Therapeutics Inc. | 125% | Options 67 · RSU 33 | No | Aon |
| Summit Therapeutics Inc. | 105% | Options 100 | not disclosed | not disclosed |
| Syndax Pharmaceuticals Inc. | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-05-21 | 56,585,568 | 2,433,537 | 84,276 | 95.88% | Passed |
| 2025 | 2025-05-14 | 52,984,920 | 1,876,215 | 5,128 | 96.58% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-05-21 | 95.88%a |
| 2025 | 2025-05-14 | 96.58%b |
a. Approved under the standard stated in the filing — “of Class A common stock present in person, by remote communication, or represented by proxy at the meeting and voting affirmatively or negatively (excluding abstentions and broker non-votes) on the matter For, Against or Abstain No Effect Not Applicable For 3 Advisory approval of the compensation of the Company's named executive officers Majority of the voting power of shares of Class A common stock present in person, by remote communication, or represented by proxy at the meeting and voting affirmatively or negatively (excluding abstentions and broker non-votes) on the matter For, Against or Abstain No Effect No Effect For What is the quorum requirement? A quorum of stockholders non-votes to exist in connection with those proposals.”.
b. Approved under the standard stated in the filing — “Abstentions will have no effect on Proposal 2, Proposal 3 and Proposal 4.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 16.3 : 1 |
|---|---|
| CEO total compensation | $6,986,410 |
| Median employee compensation | $428,720 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Marshall Fordyce | Director | 2026-04-14 | D | 7,921 | $45 | $353,106 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-04-14 | D | 900 | 46 | 40,960 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-04-14 | D | 14,130 | 44 | 616,985 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-05-12 | D | 4,281 | 37 | 158,769 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-05-12 | D | 14,219 | 37 | 520,978 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-05-12 | D | 14,219 | 37 | 520,978 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-05-12 | D | 18,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-05-12 | D | 4,281 | 37 | 158,769 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-05-12 | A | 18,500 | 3 | 53,591 | Common | Form 4 ↗ |
| Kimball Hall | Director | 2026-05-21 | A | 17,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christy Oliger | Director | 2026-05-21 | A | 17,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| James R. Meyers | Director | 2026-05-21 | A | 17,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Andrew Cheng | Director | 2026-05-21 | A | 17,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Morrissey | Director | 2026-05-21 | A | 17,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Beth C. Seidenberg | Director | 2026-05-21 | A | 17,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick G. Enright | Director | 2026-05-21 | A | 17,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Scott Morrison | Director | 2026-05-21 | A | 17,084 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-06-23 | D | 18,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-06-23 | D | 88 | 38 | 3,382 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-06-23 | D | 18,412 | 38 | 698,387 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-06-23 | D | 88 | 38 | 3,382 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-06-23 | D | 18,412 | 38 | 698,387 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-06-23 | A | 18,500 | 3 | 53,591 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 2,200 | 44 | 95,908 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 10,500 | 43 | 450,007 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 1,000 | 41 | 40,776 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 1,000 | 41 | 40,776 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | A | 46,250 | 3 | 133,977 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 32,550 | 42 | 1,369,496 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 46,250 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 2,200 | 44 | 95,908 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 10,500 | 43 | 450,007 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-07-07 | D | 32,550 | 42 | 1,369,496 | Common | Form 4 ↗ |
| Nancy Lee Boman | Chief Regulatory Officer | 2026-08-03 | A | 44,987 | 0 | 0 | Common | Form 4 ↗ |
| Nancy Lee Boman | Chief Regulatory Officer | 2026-08-03 | A | 63,011 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-09-02 | D | 18,500 | 35 | 649,642 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-09-02 | A | 18,500 | 3 | 53,591 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-09-02 | D | 18,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Joseph R. Young | SVP, Finance, Chief Acct Offcr | 2026-09-11 | A | 5,000 | 4 | 19,698 | Common | Form 4 ↗ |
| Joseph R. Young | SVP, Finance, Chief Acct Offcr | 2026-09-11 | D | 5,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-09-15 | D | 18,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-09-15 | A | 18,500 | 3 | 53,591 | Common | Form 4 ↗ |
| Marshall Fordyce | Director | 2026-09-15 | D | 18,500 | 37 | 684,500 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (95 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Marshall Fordyce. DEF 14A, filed 2026-04-09. Section “SUMMARY COMPENSATION TABLE” · page 34. As printed: 6,986,410. View filing ↗
- Section 01, David Johnson. DEF 14A, filed 2026-04-09. Section “SUMMARY COMPENSATION TABLE” · page 34. As printed: 2,721,412. View filing ↗
- Section 01, Robert Brenner. DEF 14A, filed 2026-04-09. Section “SUMMARY COMPENSATION TABLE” · page 34. As printed: 2,719,852. View filing ↗
- Section 01, Sean Grant. DEF 14A, filed 2026-04-09. Section “SUMMARY COMPENSATION TABLE” · page 34. As printed: 2,716,732. View filing ↗
- Section 01, William Turner. DEF 14A, filed 2026-04-09. Section “SUMMARY COMPENSATION TABLE” · page 34. As printed: 2,346,180. View filing ↗
- Section 03, David Johnson RSU. DEF 14A, filed 2026-04-09. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Brenner RSU. DEF 14A, filed 2026-04-09. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Marshall Fordyce RSU. DEF 14A, filed 2026-04-09. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, William Turner RSU. DEF 14A, filed 2026-04-09. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, David Johnson OPTION. DEF 14A, filed 2026-04-09. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Marshall Fordyce OPTION. DEF 14A, filed 2026-04-09. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, Robert Brenner OPTION. DEF 14A, filed 2026-04-09. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 03, William Turner OPTION. DEF 14A, filed 2026-04-09. Section “GRANTS OF PLAN-BASED AWARDS IN FISCAL 2025” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-09. Section “CEO Pay Ratio”. As printed: 16.3 : 1. View filing ↗
- Section 08, James R. Meyers. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 740,641. View filing ↗
- Section 08, Michael M. Morrissey, Ph.D. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 386,660. View filing ↗
- Section 08, Scott Morrison. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 356,660. View filing ↗
- Section 08, Patrick G. Enright. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 351,660. View filing ↗
- Section 08, Beth Seidenberg, M.D. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 346,660. View filing ↗
- Section 08, Maha Katabi, Ph.D. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 346,660. View filing ↗
- Section 08, Andrew Cheng, M.D., Ph.D. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 344,160. View filing ↗
- Section 08, Kimball Hall. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 344,160. View filing ↗
- Section 08, Christy Oliger. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 341,660. View filing ↗
- Section 08, Marshall Fordyce, M.D. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Christopher Hite. DEF 14A, filed 2026-04-09. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, Marshall Fordyce 2026-04-14. Form 4, filed 2026-04-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-04-14. Form 4, filed 2026-04-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-04-14. Form 4, filed 2026-04-15. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-05-12. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-05-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-05-12. Form 4, filed 2026-05-13. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-05-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-05-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-05-12. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kimball Hall 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Christy Oliger 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, James R. Meyers 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Andrew Cheng 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Michael Morrissey 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Beth C. Seidenberg 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick G. Enright 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Scott Morrison 2026-05-21. Form 4, filed 2026-05-26. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-06-23. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-06-23. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-06-23. Form 4, filed 2026-06-24. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-06-23. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-06-23. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-06-23. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-07-09. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-07-07. Form 4, filed 2026-08-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Lee Boman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nancy Lee Boman 2026-08-03. Form 4, filed 2026-08-05. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-09-02. Form 4, filed 2026-09-04. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph R. Young 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Joseph R. Young 2026-09-11. Form 4, filed 2026-09-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Marshall Fordyce 2026-09-15. Form 4, filed 2026-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-05-26. Item 5.07 · say-on-pay result. As reported: 95.88% (votes for as printed: 56,585,568). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-05-19. Item 5.07 · say-on-pay result. As reported: 96.58% (votes for as printed: 52,984,920). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 449,891 + equity 0 + all other 0 = 449,891, summed across the director compensation table rows.
- Summit Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Summit Therapeutics Inc.'s own proxy. As printed: 246,047,279. View filing ↗
- Soleno Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2025-04-22. CEO total compensation as printed in Soleno Therapeutics Inc.'s own proxy. As printed: 51,160,430. View filing ↗
- Cogent Biosciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Cogent Biosciences Inc.'s own proxy. As printed: 27,762,684. View filing ↗
- Arcellx Inc., Section 10b CEO total. DEF 14A, filed 2025-04-17. CEO total compensation as printed in Arcellx Inc.'s own proxy. As printed: 21,402,668. View filing ↗
- Immunovant Inc., Section 10b CEO total. DEF 14A, filed 2026-07-22. CEO total compensation as printed in Immunovant Inc.'s own proxy. As printed: 20,158,767. View filing ↗
- Avidity Biosciences Inc., Section 10b CEO total. DEF 14A, filed 2025-04-29. CEO total compensation as printed in Avidity Biosciences Inc.'s own proxy. As printed: 14,176,480. View filing ↗
- Protagonist Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-28. CEO total compensation as printed in Protagonist Therapeutics Inc.'s own proxy. As printed: 12,871,506. View filing ↗
- Crinetics Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Crinetics Pharmaceuticals Inc.'s own proxy. As printed: 11,628,959. View filing ↗
- Akero Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2025-04-28. CEO total compensation as printed in Akero Therapeutics Inc.'s own proxy. As printed: 10,465,855. View filing ↗
- Ideaya Biosciences Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Ideaya Biosciences Inc.'s own proxy. As printed: 9,512,640. View filing ↗
- Kymera Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Kymera Therapeutics Inc.'s own proxy. As printed: 8,545,609. View filing ↗
- Structure Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Structure Therapeutics Inc.'s own proxy. As printed: 8,429,887. View filing ↗
- Syndax Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Syndax Pharmaceuticals Inc.'s own proxy. As printed: 7,089,213. View filing ↗
- Vera Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in Vera Therapeutics, Inc.'s own proxy. As printed: 6,986,410. View filing ↗
- Spyre Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-10. CEO total compensation as printed in Spyre Therapeutics Inc.'s own proxy. As printed: 6,707,361. View filing ↗
- AnaptysBio Inc., Section 10b CEO total. DEF 14A, filed 2026-06-29. CEO total compensation as printed in AnaptysBio Inc.'s own proxy. As printed: 6,133,943. View filing ↗
- Pliant Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-22. CEO total compensation as printed in Pliant Therapeutics Inc.'s own proxy. As printed: 5,462,901. View filing ↗
- Celldex Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Celldex Therapeutics Inc.'s own proxy. As printed: 5,366,709. View filing ↗
- Neumora Therapeutics Inc., Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Neumora Therapeutics Inc.'s own proxy. As printed: 4,562,461. View filing ↗
- Section 10a, Soleno Therapeutics Inc. reciprocity. DEF 14A. Soleno Therapeutics Inc. names Vera Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Spyre Therapeutics Inc. reciprocity. DEF 14A. Spyre Therapeutics Inc. names Vera Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, Kymera Therapeutics Inc. reciprocity. DEF 14A. Kymera Therapeutics Inc. names Vera Therapeutics, Inc. in its own disclosed peer group (read from its most recent proxy). View filing ↗